牛牛AI助理已提取核心訊息
AbbVie Inc., a biopharmaceutical company, has successfully completed the acquisition of ImmunoGen, Inc., a leader in antibody-drug conjugates for cancer treatment, as of February 12, 2024. This follows the Merger Agreement entered into on November 30, 2023. In accordance with the terms of the Merger Agreement, AbbVie has assumed the ImmunoGen Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan and the ImmunoGen Inducement Equity Incentive Plan, as amended. Outstanding restricted stock unit awards under these plans have been converted into awards for AbbVie common stock. The company has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission to register the common stock issuable upon the settlement of the converted awards. This move is part of AbbVie's strategic efforts to expand its oncology portfolio and leverage ImmunoGen's expertise in the development of targeted therapies for cancer patients.
AbbVie Inc., a biopharmaceutical company, has successfully completed the acquisition of ImmunoGen, Inc., a leader in antibody-drug conjugates for cancer treatment, as of February 12, 2024. This follows the Merger Agreement entered into on November 30, 2023. In accordance with the terms of the Merger Agreement, AbbVie has assumed the ImmunoGen Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan and the ImmunoGen Inducement Equity Incentive Plan, as amended. Outstanding restricted stock unit awards under these plans have been converted into awards for AbbVie common stock. The company has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission to register the common stock issuable upon the settlement of the converted awards. This move is part of AbbVie's strategic efforts to expand its oncology portfolio and leverage ImmunoGen's expertise in the development of targeted therapies for cancer patients.
截至2024年2月12日，生物製藥公司艾伯維公司已成功完成對癌症治療抗體藥物偶聯物的領導者ImmunoGen, Inc. 的收購。這是繼2023年11月30日簽訂的合併協議之後發生的。根據合併協議的條款，艾伯維接管了ImmunoGen修正和重述的2018年員工、董事和顧問股權激勵計劃以及經修訂的ImmunoGen激勵股權激勵計劃。這些計劃下未償還的限制性股票單位獎勵已轉換爲艾伯維普通股的獎勵。該公司已向美國證券交易委員會提交了S-8表格的註冊聲明，要求在結算轉換後的獎勵後註冊可發行的普通股。此舉是艾伯維戰略努力的一部分，旨在擴大其腫瘤學產品組合，並利用ImmunoGen在爲癌症患者開發靶向療法方面的專業知識。
截至2024年2月12日，生物製藥公司艾伯維公司已成功完成對癌症治療抗體藥物偶聯物的領導者ImmunoGen, Inc. 的收購。這是繼2023年11月30日簽訂的合併協議之後發生的。根據合併協議的條款，艾伯維接管了ImmunoGen修正和重述的2018年員工、董事和顧問股權激勵計劃以及經修訂的ImmunoGen激勵股權激勵計劃。這些計劃下未償還的限制性股票單位獎勵已轉換爲艾伯維普通股的獎勵。該公司已向美國證券交易委員會提交了S-8表格的註冊聲明，要求在結算轉換後的獎勵後註冊可發行的普通股。此舉是艾伯維戰略努力的一部分，旨在擴大其腫瘤學產品組合，並利用ImmunoGen在爲癌症患者開發靶向療法方面的專業知識。
有用
沒用